Literature DB >> 6165266

Interferon-induced disease in mice and rats.

I Gresser, L Morel-Maroger, Y Rivière, J C Guillon, M G Tovey, D Woodrow, J C Sloper, J Moss.   

Abstract

Treatment of newborn mice with potent mouse interferon preparations resulted in an acute "early" syndrome characterized by inhibition of growth, delay in maturation of several organs, diffuse liver cell necrosis and death. When interferon treatment was discontinued at 1 week of life, mice appeared to recover, but subsequently developed a progressive glomerulonephritis ("late syndrome"). Treatment of newborn rats with potent rat interferon preparations also resulted in inhibition of growth, delay in maturation, and the subsequent development of glomerulonephritis. After infection at birth with lymphocyte choriomeningitis (LCM) virus, most strains of mice developed a similar acute early syndrome and surviving mice subsequently developed glomerulonephritis. We postulated that the endogenous interferon induced by LCM virus early in life was partially responsible for these syndromes. Administration of a potent anti-mouse interferon serum to LCM virus-infected mice neutralized the circulating endogenous interferon and inhibited the development of both the early and late syndromes. Our results suggest that large amounts of exogenous or endogenous interferon at a crucial stage of rapid growth or development of mice and rats can induce lesions in several different organs. Some lesions (i.e. the kidney) only become apparent weeks or even months after exposure to interferon.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6165266     DOI: 10.1111/j.1749-6632.1980.tb20602.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  20 in total

1.  CCR2 Signaling Selectively Regulates IFN-α: Role of β-Arrestin 2 in IFNAR1 Internalization.

Authors:  Dionna W Williams; Lauren C Askew; Elonna Jones; Janice E Clements
Journal:  J Immunol       Date:  2018-11-30       Impact factor: 5.422

2.  Loss of function of PCDH12 underlies recessive microcephaly mimicking intrauterine infection.

Authors:  Adi Aran; Nuphar Rosenfeld; Ranit Jaron; Paul Renbaum; Shachar Zuckerman; Hila Fridman; Sharon Zeligson; Reeval Segel; Yoav Kohn; Lara Kamal; Moien Kanaan; Yoram Segev; Eyal Mazaki; Ron Rabinowitz; Ori Shen; Ming Lee; Tom Walsh; Mary Claire King; Suleyman Gulsuner; Ephrat Levy-Lahad
Journal:  Neurology       Date:  2016-04-29       Impact factor: 9.910

3.  A Brief Historical Perspective on the Pathological Consequences of Excessive Type I Interferon Exposure In vivo.

Authors:  Yanick J Crow; Pierre Lebon; Jean-Laurent Casanova; Ion Gresser
Journal:  J Clin Immunol       Date:  2018-09-05       Impact factor: 8.317

4.  Constitutively Active MDA5 Proteins Are Inhibited by Paramyxovirus V Proteins.

Authors:  Roli Mandhana; Lily K Qian; Curt M Horvath
Journal:  J Interferon Cytokine Res       Date:  2018-08       Impact factor: 2.607

Review 5.  Aicardi-Goutières syndrome and the type I interferonopathies.

Authors:  Yanick J Crow; Nicolas Manel
Journal:  Nat Rev Immunol       Date:  2015-06-05       Impact factor: 53.106

6.  Interferon-induced transmembrane proteins inhibit cell fusion mediated by trophoblast syncytins.

Authors:  Ashley Zani; Lizhi Zhang; Temet M McMichael; Adam D Kenney; Mahesh Chemudupati; Jesse J Kwiek; Shan-Lu Liu; Jacob S Yount
Journal:  J Biol Chem       Date:  2019-11-17       Impact factor: 5.157

7.  Band-like calcification with simplified gyration and polymicrogyria: report of 10 new families and identification of five novel OCLN mutations.

Authors:  Mohamed S Abdel-Hamid; Ghada M H Abdel-Salam; Mahmoud Y Issa; Bayoumi A Emam; Maha S Zaki
Journal:  J Hum Genet       Date:  2017-02-09       Impact factor: 3.172

8.  Serum interferon in Navajo children with severe combined immunodeficiency disease inhibits lymphoblastogenesis.

Authors:  J F Jones; L M Minnich; D O Lucas; V A Fulginiti; Z Ingham; M P Langford; G J Stanton
Journal:  J Clin Immunol       Date:  1983-01       Impact factor: 8.317

9.  Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study.

Authors:  Gillian I Rice; Gabriella M A Forte; Marcin Szynkiewicz; Diana S Chase; Alec Aeby; Mohamed S Abdel-Hamid; Sam Ackroyd; Rebecca Allcock; Kathryn M Bailey; Umberto Balottin; Christine Barnerias; Genevieve Bernard; Christine Bodemer; Maria P Botella; Cristina Cereda; Kate E Chandler; Lyvia Dabydeen; Russell C Dale; Corinne De Laet; Christian G E L De Goede; Mireia Del Toro; Laila Effat; Noemi Nunez Enamorado; Elisa Fazzi; Blanca Gener; Madli Haldre; Jean-Pierre S-M Lin; John H Livingston; Charles Marques Lourenco; Wilson Marques; Patrick Oades; Pärt Peterson; Magnhild Rasmussen; Agathe Roubertie; Johanna Loewenstein Schmidt; Stavit A Shalev; Rogelio Simon; Ronen Spiegel; Kathryn J Swoboda; Samia A Temtamy; Grace Vassallo; Catheline N Vilain; Julie Vogt; Vanessa Wermenbol; William P Whitehouse; Doriette Soler; Ivana Olivieri; Simona Orcesi; Mona S Aglan; Maha S Zaki; Ghada M H Abdel-Salam; Adeline Vanderver; Kai Kisand; Flore Rozenberg; Pierre Lebon; Yanick J Crow
Journal:  Lancet Neurol       Date:  2013-10-30       Impact factor: 44.182

10.  Inhibition of the type I interferon antiviral response during arenavirus infection.

Authors:  Persephone Borrow; Luis Martínez-Sobrido; Juan Carlos de la Torre
Journal:  Viruses       Date:  2010-11-05       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.